On January 21, 2021 NexImmune reported that hiring of Gilead Sciences and Kite Pharma alum Robert Knight, M.D., the T-cell biotech is now gunning for an $86 million IPO (Press release, NexImmune, JAN 21, 2021, View Source [SID1234574228]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The startup wants the cash to boost its work on immunotherapy, with its platform designed to employ the body’s own T cells to generate a potent and durable immune response that mimics natural biology.
"Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases," the Maryland biotech said in its Securities and Exchange Commission filing.
SPONSORED BY SYNEOS HEALTH
Blazing a Trail to Clinical Trial Diversity: Four-Part Webinar Series from Syneos Health, Featuring Pharma, Clinical Research and Community Health Leaders
This series will identify obstacles that stifle appropriate patient diversity in trials; unpack the organizational overhaul needed; share how sponsors, patients & investigators have come together to overcome hurdles; and explore how policy innovations can move the industry forward.
REGISTER NOW
It’s early-stage but in the clinic, unusually for a lot of biotech IPO attempts these days, with two candidates in human trials: NEXI-001 in acute myeloid leukemia (AML) and NEXI-002 in multiple myeloma (MM). Early data for these should be out by year-end.
NEXI-001 is a donor-derived, or allogeneic, ACT in a phase 1/2 test for treatment of patients with relapsed AML after allogeneic stem cell transplantation. NEXI-002, meanwhile, is a patient-derived, or autologous, ACT in a phase 1/2 for MM patients that have failed at least three prior lines of therapy.
"The backbone of our approach is our proprietary Artificial Immune Modulation, or AIM, nanoparticle technology platform. The AIM technology enables us to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. Like natural dendritic cells, the AIM nanoparticles employ natural signaling proteins to deliver specific instructions to specific T cells directing a desired immune response," the company said in the filing.
It said what sets it apart is, unlike other cell therapy approaches, it’s is accomplished "without any genetic manipulation of the T cell," thereby creating T-cell products designed to maintain natural target identification, engagement and killing mechanisms.
It now has Knight on board to help with the approach and can tap his vast experience in immunotherapy, which includes work on cell therapy Yescarta with Gilead-Kite as well as stints at Celgene and Sorrento.
The decade-old company, which licensed its core AIM tech from Johns Hopkins University, plans to list on the Nasdaq under the symbol "NEXI."